Loading
Latest filing published 02 Apr 2026 for Innovent Biologics, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Sherwin Stephen A. on record concern Innovent Biologics, Inc., in the capacity of chief executive. Over a trading history stretching from 29 August 2025 to 30 March 2026, the count stands at 2 filings.
Purchases make up the whole of the open-market record (2 purchases). The totals do not cover 2 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.
The record was last updated on 2 April 2026 with an open-market purchase in Innovent Biologics, Inc. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration